Exploring the acceptor substrate recognition of the human beta-galactoside alpha 2,6-sialyltransferase.
Human beta1,4-galactoside alpha2,6-sialyltransferase I (ST6GalI) recognition of glycoprotein acceptors has been investigated using various soluble forms of the enzyme deleted to a variable extent in the N-terminal half of the polypeptide. Full-length and truncated forms of the enzyme have been investigated with respect to their specificity for a variety of desialylated glycoproteins of known complex glycans as well as related proteins with different carbohydrate chains. Differences in transfer efficiency have been observed between membrane and soluble enzymatic forms, indicating that deletion of the transmembrane fragment induces loss of acceptor preference. No difference in substrate recognition could be observed when soluble enzymes of similar peptide sequence were produced in yeast or mammalian cells, confirming that removal of the membrane anchor and heterologous expression do not alter enzyme folding and activity. When tested on free oligosaccharides, soluble ST6GalI displayed full ability to sialylate free N-glycans as well as various N-acetyllactosaminyl substrates. Progressive truncation of the N terminus demonstrated that the catalytic domain can proceed with sialic acid transfer with increased efficiency until 80 amino acids are deleted. Fusion of the ST6GalI catalytic domain to the N-terminal half of an unrelated transferase (core 2 beta1,6-N-acetylglucosaminyltransferase) further showed that a chimeric form of broad acceptor specificity and high activity could also be engineered in vivo. These findings therefore delineate a peptide region of approximately 50 amino acids within the ST6GalI stem region that governs both the preference for glycoprotein acceptors and catalytic activity, thereby suggesting that it may exert a steric control on the catalytic domain.
Legaigneur
P
P
CNRS UPR 9024, 31 Chemin Joseph Aiguier, F-13402 Marseille Cedex 20, France.
Breton
C
C
El Battari
A
A
Guillemot
J C
JC
Auge
C
C
Malissard
M
M
Berger
E G
EG
Ronin
C
C
D000818:Animals; D001665:Binding Sites; D016466:CHO Cells; D020134:Catalytic Domain; D003001:Cloning, Molecular; D006224:Cricetinae; D003569:Cytidine Monophosphate N-Acetylneuraminic Acid / Q000378:metabolism; D014644:Genetic Variation; D006801:Humans; D007700:Kinetics; D009961:Orosomucoid / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D017384:Sequence Deletion; D012799:Sialyltransferases / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D013379:Substrate Specificity; D013972:Thyrotropin / Q000378:metabolism; D014162:Transfection; D014168:Transferrin / Q000378:metabolism; D000509:alpha-Fetoproteins / Q000378:metabolism; D000094802:beta-D-Galactoside alpha 2-6-Sialyltransferase
D009961:Orosomucoid; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D014168:Transferrin; D000509:alpha-Fetoproteins; D003569:Cytidine Monophosphate N-Acetylneuraminic Acid; D013972:Thyrotropin; D012799:Sialyltransferases; D000094802:beta-D-Galactoside alpha 2-6-Sialyltransferase